Dyadic International, Inc. Expected to Earn FY2024 Earnings of ($0.28) Per Share (NASDAQ:DYAI)

Dyadic International, Inc. (NASDAQ:DYAI) – Investment analysts at Zacks Small Cap lifted their FY2024 earnings per share (EPS) estimates for Dyadic International in a research note issued on Wednesday, May 15th. Zacks Small Cap analyst J. Vandermosten now forecasts that the biotechnology company will post earnings per share of ($0.28) for the year, up from their prior forecast of ($0.66). The consensus estimate for Dyadic International’s current full-year earnings is ($0.44) per share. Zacks Small Cap also issued estimates for Dyadic International’s FY2025 earnings at ($0.32) EPS.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter. Dyadic International had a negative net margin of 347.92% and a negative return on equity of 116.14%. The firm had revenue of $0.33 million during the quarter. During the same quarter in the prior year, the company posted ($0.03) earnings per share.

Dyadic International Stock Performance

Dyadic International stock opened at $1.65 on Friday. Dyadic International has a 1-year low of $1.19 and a 1-year high of $2.40. The company’s 50-day moving average is $1.60 and its 200 day moving average is $1.56. The firm has a market capitalization of $48.25 million, a P/E ratio of -5.89 and a beta of 0.63. The company has a debt-to-equity ratio of 1.29, a current ratio of 5.54 and a quick ratio of 3.58.

Institutional Investors Weigh In On Dyadic International

A hedge fund recently bought a new stake in Dyadic International stock. Callan Capital LLC bought a new position in shares of Dyadic International, Inc. (NASDAQ:DYAI) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned about 0.09% of Dyadic International at the end of the most recent quarter. 27.95% of the stock is currently owned by institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.